Type 2 diabetes and metabolic syndrome
NAMSNewAmsterdam Pharma Company NVCatalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for Obicetrapib + ezetimibe in Type 2 diabetes and metabolic syndrome. The expected timing is based on the latest available company guidance and may change.
RUBENS trial. Planned launch of Ph3 trial later in 2025. 11/05/25:- RUBENS Phase 3 trial in type 2 diabetes/metabolic syndrome expected to initiate in Q4 2025. 02/18/26:- RUBENS Ph3 trial initiated December 2025; approximately 300 patients; topline LDL-C data expected by year-end 2026. 05/07/26:- RUBENS Phase 3 in type 2 diabetes/metabolic syndrome ongoing; topline LDL-C data expected by year-end 2026. 08/05/26:- RUBENS enrollment near 300 patients; topline data remain expected YE 2026.
Verification
Confirm timing and program details against the company announcement or filing.